Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form

Tabarsi et al., Iranian Journal of Pharmaceutical Research, doi:10.22037/ijpr.2021.115510.15401
Sep 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 30% Improvement Relative Risk ICU admission 41% <50% improvement in che.. 6% Hospitalization time 25% Favipiravir  Tabarsi et al.  LATE TREATMENT  RCT Is late treatment with favipiravir beneficial for COVID-19? RCT 62 patients in Iran (April - May 2020) Trial compares with lopinavir/ritonavir, results vs. placebo may differ Shorter hospitalization with favipiravir (p=0.03) Tabarsi et al., Iranian J. Pharmaceuti.., Sep 2021 Favorsfavipiravir Favorslopinavir/ri.. 0 0.5 1 1.5 2+
Small 62 patient late stage RCT in Iran comparing favipiravir and lopinavir/ritonavir, showing significant improvement in fever, cough, and dyspnea with favipiravir on day 5. There was no significant difference in mortality, ICU admission, or chest CT improvement. IRCT20151227025726N14.
risk of death, 29.7% lower, RR 0.70, p = 0.70, treatment 3 of 32 (9.4%), control 4 of 30 (13.3%), NNT 25.
risk of ICU admission, 41.4% lower, RR 0.59, p = 0.36, treatment 5 of 32 (15.6%), control 8 of 30 (26.7%), NNT 9.1.
risk of <50% improvement in chest CT, 6.2% lower, RR 0.94, p = 0.76, treatment 24 of 32 (75.0%), control 24 of 30 (80.0%), NNT 20.
hospitalization time, 25.0% lower, relative time 0.75, p = 0.03, treatment 32, control 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tabarsi et al., 30 Sep 2021, Randomized Controlled Trial, Iran, peer-reviewed, 27 authors, study period 4 April, 2020 - 7 May, 2020, average treatment delay 7.0 days, this trial compares with another treatment - results may be better when compared to placebo.
This PaperFavipiravirAll
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
Payam Tabarsi, Hossein Vahidi, Ali Saffaei, Seyed Mohammad, Reza Hashemian, Hamidreza Jammati, Bahram Daraei, Arash Mahboubi, Farzad Kobarfard, Majid Marjani, Afshin Moniri, Zahra Abtahian, Atefeh Abedini, Alireza Eslaminejad, Jalal Heshmatnia, Maryam Sadat Mirenayat, Atefeh Fakharian, Sharareh Seifi, Mohsen Sadeghi, Alireza Dastan, Sara Haseli, Seyed Alireza, Raha Eskandari, Sahar Yousefian, Mohammad Varahram, Alireza Za, Ali Akbar Velayati, Farzaneh Dastan
Coronavirus disease -19 (COVID-19) pandemic, caused by SARS-CoV-2, has gradually spread worldwide, becoming a major public health event. This situation requires designing a novel antiviral agent against the SARS-CoV-2; however, this is time-consuming and the use of repurposed medicines may be promising. One such medicine is favipiravir, primarily introduced as an anti-influenza agent in east world. The aim of this study was to evaluate the efficacy and safety of favipiravir in comparison with lopinavir-ritonavir in SARS-CoV-2 infection. In this randomized clinical trial, 62 patients were recruited. These patients had bilateral pulmonary infiltration with peripheral oxygen saturation lower than 93%. The median time from symptoms onset to intervention initiation was seven days. Favipiravir was not available in the Iranian pharmaceutical market, and it was decided to formulate it at the
Boretti, Favipiravir use for SARS CoV-2 infection, Pharmacol. Rep
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Coomes, Haghbayan, Favipiravir, an antiviral for COVID-19?, J. Antimicrob. Chemother
Dastan, Nadji, Saffaei, Tabarsi, Tocilizumab administration in a refractory case of COVID-19, Int. J. Antimicrob. Agents
Dastan, Tabarsi, Marjani, Moniri, Hashemian et al., Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces, Iran. J. Pharm. Res
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther
Gioia, Ciaccio, Simone, Fasciglione, Di Masi et al., Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches, Biochem. Pharmacol
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin. Infect. Dis
Jordan, Stevens, Deval, Nucleosides for the treatment of respiratory RNA virus infections, Antivir. Chem. Chemother
Joseph, Dibas, Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review, Expert Rev. Anti Infect. Ther
Lambert, Petteway, Mcdanal, Hart, Leary et al., Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells, Antimicrob. Agents Chemother
Pan, Ye, Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19), Radiology
Reddy, Lai, Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options, Chembiochem
Rosa, Santos, Clinical trials on drug repositioning for COVID-19 treatment, Rev. Panam. Salud. Publica
Takian, Raoofi, Kazempour-Ardebili, COVID-19 battle during the toughest sanctions against Iran, Lancet
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis
Vakili, Fathi, Pezeshgi, Mohamadkhani, Hajiesmaeili et al., Critical complications of COVID-19: A descriptive meta-analysis study, Rev. Cardiovasc. Med
{ 'type': 'article-journal', 'language': 'eng', 'journalAbbreviation': 'IJPR', 'author': [ {'family': 'Tabarsi', 'given': 'Payam'}, {'family': 'Vahidi', 'given': 'Hossein'}, {'family': 'Saffaei', 'given': 'Ali'}, {'family': 'Hashemian', 'given': 'Seyed Mohammad Reza'}, {'family': 'Jamaati', 'given': 'Hamidreza'}, {'family': 'Daraei', 'given': 'Bahram'}, {'family': 'Mahboubi', 'given': 'Arash'}, {'family': 'Kobarfard', 'given': 'Farzad'}, {'family': 'Marjani', 'given': 'Majid'}, {'family': 'Moniri', 'given': 'Afshin'}, {'family': 'Abtahian', 'given': 'Zahra'}, {'family': 'Abedini', 'given': 'Atefeh'}, {'family': 'Eslaminejad', 'given': 'Alireza'}, {'family': 'Heshmatnia', 'given': 'Jalal'}, {'family': 'Mirenayat', 'given': 'Maryam Sadat'}, {'family': 'Fakharian', 'given': 'Atefeh'}, {'family': 'Seifi', 'given': 'Sharareh'}, {'family': 'Sadeghi', 'given': 'Mohsen'}, {'family': 'Dastan', 'given': 'Alireza'}, {'family': 'Haseli', 'given': 'Sara'}, {'family': 'Nadji', 'given': 'Seyed Alireza'}, {'family': 'Eskandari', 'given': 'Raha'}, {'family': 'Yousefian', 'given': 'Sahar'}, {'family': 'Varahram', 'given': 'Mohammad'}, {'family': 'Zali', 'given': 'Alireza'}, {'family': 'Velayati', 'given': 'Ali Akbar'}, {'family': 'Dastan', 'given': 'Farzaneh'}], 'issued': {'date-parts': [[2021, 12]]}, 'container-title': 'Iranian Journal of Pharmaceutical Research', 'container-title-short': 'IJPR', 'DOI': '10.22037/ijpr.2021.115510.15401', 'issue': '4', 'publisher': 'School of Pharmacy, Shahid Beheshti University of Medical Sciences', 'publisher-place': 'IR', 'title': 'Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An ' 'Experience with Iranian Formulated Dosage Form', 'URL': '', 'volume': '20'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop